Oncology

Myelofibrosis

Expert Roundtables Podcast: Addressing Unmet Needs in Myelofibrosis

expert roundtables by Aaron T. Gerds, MD, MS; Stephen T. Oh, MD, PhD; Raajit K. Rampal, MD, PhD

Overview

<p>Although available therapies for myelofibrosis have improved, there are still unmet needs to address, including managing anemia, sequencing therapies after disease progression (particularly JAK inhibitors), and using combination therapies to try to delay the development of progression. Join our expert panelists as they discuss addressing unmet needs in myelofibrosis.</p>

References

ClinicalTrials.gov. A study of JNJ-88549968 for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasms. Updated July 20, 2025. Accessed July 21, 2025. https://clinicaltrials.gov/study/NCT06150157

ClinicalTrials.gov. A study to evaluate INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms. Updated June 22, 2025. Accessed July 21, 2025. https://clinicaltrials.gov/study/NCT05936359

Jain AG, Gerds AT. How I treat anemia in myelofibrosis. Blood. 2025;145(16):1738-1746. doi:10.1182/blood.2023022414

Khan MA, Palmer J. SOHO State of the Art Updates and Next Questions | updates on myelofibrosis with cytopenia. Clin Lymphoma Myeloma Leuk. 2025;25(5):293-303. doi:10.1016/j.clml.2024.09.002

Kong T, Laranjeira ABA, Letson CT, et al. RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat Commun. 2025;16(1):492. doi:10.1038/s41467-024-55643-7

Mascarenhas JO, Rampal R, El Chaer F, et al. A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis. Blood. 2024;144(suppl 1):6629. doi:10.1182/blood-2024-200268

Pemmaraju N, Mead AJ, Somervaille TCP, et al. TRANSFORM-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Blood. 2023;142(suppl 1):620. doi:10.1182/blood-2023-173509

Rampal R, Grosicki S, Chraniuk D, et al. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis. J Clin Oncol. 2024;42(suppl 16):6502. doi:10.1200/JCO.2024.42.16_suppl.6502

Profile

Aaron T. Gerds, MD, MS

Associate Professor of Medicine

Deputy Directory for Clinical Research

Cleveland Clinic Taussig Cancer Institute

Medical Director

Case Comprehensive Cancer Center Clinical Research Office

Case Western Reserve University

Cleveland, OH

Profile

Stephen T. Oh, MD, PhD

Associate Professor and Co-Chief
Division of Hematology
John T. Milliken Department of Medicine
Washington University School of Medicine
St. Louis, MO

Profile

Raajit K. Rampal, MD, PhD

Associate Member
Director, Myeloproliferative Neoplasms Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, NY